The committee is holding an inquiry into clinical trials, given that the European Commission is proposing to revise the directive that regulates trials in the UK. The inquiry also comes amid concerns raised about transparency and disclosure of all clinical trial data: drug companies are entitled to conduct numerous clinical trials on drugs but publish results selectively.
The MPs asked whether there was real evidence of some trial results being withheld.
Fiona Godlee, editor in chief of the BMJ, giving evidence, said, "There is a great deal of evidence and some cases that have been well investigated suggesting that evidence is withheld, whether on purpose or as a result of the system that we currently use.
"There have been a number of well known cases where drugs have been approved based on incomplete information-and where subsequently that information has been provided and the drug has been found to be either ineffective or actually harmful.
"As for whether the regulator gets all the information, this is something which I think is still rather murky."
Michael Rawlins, chairman of the National Institute for Health and Clinical Excellence (NICE), also giving evidence, said that the institute, when considering a drug or treatment, insisted that a medical director confirm that all relevant information had been provided.
Rawlins, who also chaired a recent Academy of Medical Sciences review of medical sciences regulation and governance, said, "The problem is that if things are being concealed from us, and particularly if they are being concealed from the medical director in Britain, we won't know about it." Fellow witness Keith Bragman, president of the Faculty of Pharmaceutical Medicine, said, "There is a problem. Most people who are practising pharmaceutical medicine and developing novel medicines are doing the right thing, but unfortunately there are a number of individuals-I hope a small minority-who need to be compelled to do the right thing.
"We need registration of all clinical trials. We need results, and we need access to the data so that people can validate observations. "If we do not know what we can believe, then the whole system suffers. Belief in medicine suffers, patients don't take their medicines properly, the benefits that can be derived from medicines suffer, and it costs the NHS more."
MPs asked what the main barriers were to conducting clinical trials in the UK.
Rawlins said, "Apart from the clinical trials directive, which is generally regarded as very flawed, there are two main barriers: first of all is the plethora of ethical approvals that need to be sometimes garnered in order to embark on a clinical trial.
"By far the greatest impediment to doing clinical trials in Britain has been the fact that each individual trust-if you are doing a multicentre trial, and most trials are-takes on itself its own governance arrangements looking at things like criminal records reviews, patient consent forms, and the contracts going to their lawyers.
"We met one woman who had been a principal investigator in a study involving 62 hospitals, because it was a rare disease, and she had had 62 CRB [Criminal Records Bureau] checks." Bragman said, "The problems are very much focused on issues of governance: problems in getting contracts negotiated with many different area health authorities and bureaucracies. These things are making clinical research increasingly unattractive here in the UK."
